title: Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration.
abstract: Post-operative management of differentiated thyroid cancer (DTC) often involves administration of radioactive iodine (RAI) for remnant ablation or adjuvant therapy. However, given the favorable prognosis associated with DTC, the risk versus benefit ratio of RAI remains unclear. RAI is associated with substantial, albeit rare side effects, including a possible increased risk of secondary malignancy and altered fertility, which must be balanced against the magnitude of benefit for decreasing recurrence and improving survival.
authors.affiliation: Division of Breast/Soft Tissue and Endocrine Surgery, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
authors.forename: Supriya S
authors.initials: SS
authors.lastname: Patel
authors.forename: Melanie
authors.initials: M
authors.lastname: Goldfarb
mesh_terms: D055011:Ablation Techniques / Q000379:methods; D018263:Adenocarcinoma, Follicular / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D000367:Age Factors; D002277:Carcinoma / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D002291:Carcinoma, Papillary; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local; D018579:Patient Selection; D011829:Radiation Dosage; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use*; D018714:Radiotherapy, Adjuvant; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D013965:Thyroidectomy; D016896:Treatment Outcome
chemical_list: D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals